PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status

The novel agent PRIMA-1met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1met may therefore act independently of MTp53 status and WTp53 transactivation.